The success of Sildenafil initially sparked a surge for pharma, however recent developments present a uncertain scenario for investors. Lower-cost versions are reducing earnings, and ongoing litigation add additional https://roryjfld576510.mpeblog.com/74352169/viagra-and-big-pharma-a-risky-bet